98%
921
2 minutes
20
The aim of this nationwide longitudinal cohort study is to determine the risk of congestive heart failure (CHF) associated with a seropositive rheumatoid arthritis (RA) population in Korea. In this study, National Health Insurance Service-Health Screening Cohort (NHIS-HEALS) data from 2002 to 2003 were used. The cohort was followed up with for 12 years until December of 2015. Seropositive RA was defined as a patient prescribed with a disease-modifying anti-rheumatic drug (DMARD) among patients with the International Classification of Diseases code M05 (seropositive RA). Patients who were diagnosed before 2004 were excluded. The seropositive RA group consisted of 2765 patients, and a total of 13,825 patients were in the control group. The Kaplan-Meier method was used to calculate the 12-year CHF incidence rate for each group. A Cox proportional hazards regression analysis was used to estimate the hazard ratio of CHF. The hazard ratio of CHF in the seropositive RA group was 2.41 (95% confidence interval (CI): 1.40-4.14) after adjusting for age and sex. The adjusted hazard ratio of CHF in the seropositive RA group was 2.50 (95% CI: 1.45-4.30) after adjusting for age, sex, income, and comorbidities. In females aged ≥65 and aged <65, the incidence rates in the non-hypertension, non-diabetes mellitus, and non-dyslipidemia subgroups were significantly higher in the seropositive RA group than in the control group. This nationwide longitudinal cohort study shows an increased risk of CHF in patients with seropositive RA.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11204740 | PMC |
http://dx.doi.org/10.3390/jpm14060615 | DOI Listing |
Korean J Intern Med
September 2025
Hanyang University Institute for Rheumatology Research, Seoul, Korea.
Background/aims: To identify factors associated with achieving low disease activity (LDA) after 48 weeks of targeted therapy in patients with rheumatoid arthritis (RA) despite not meeting treat-to-target (T2T) criteria at week 24.
Methods: Data were collected from a multicenter, prospective observational cohort of Korea patients with RA receiving targeted therapy between April 2020 and July 2023. Patients who continued their initial targeted therapy despite not achieving LDA at week 24 were assigned to the LDA and non-LDA groups at week 48.
Parasitol Int
September 2025
Immunoparasitology Laboratory, Faculty of Veterinary Science-La Plata National University, La Plata, 1900 Buenos Aires, Argentina; National Scientific and Technical Research Council (CONICET), Ciudad Autónoma de Buenos Aires (C1425FQB), Argentina; Institute of Parasitology, University of Bern, Län
The apicomplexan protozoa Neospora caninum, Sarcocystis spp. and Toxoplasma gondii are worldwide distributed. Goat infections with these protozoans are frequent, although the relationship with milk production is unknown.
View Article and Find Full Text PDFPLoS Negl Trop Dis
September 2025
Environmental Health Group, Faculty of Infectious Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Background: Chikungunya virus (CHIKV) is an arbovirus with a significant global public health burden. Delineating the specific contributions of individual behaviour, household, natural and built environment to CHIKV transmission is important for reducing risk in urban informal settlements but challenging due to their heterogeneous environments. The aim of this study was to quantify variation in CHIKV seroprevalence between and within four urban communities in a large Brazilian city, and identify the respective contributions of individual, household, and environmental factors for seropositivity.
View Article and Find Full Text PDFJ Med Virol
September 2025
Department of Endocrinology, University of Health Sciences Ankara Etlik City Hospital, Ankara, Türkiye.
Human herpesvirus 8 (HHV-8) positivity rates vary across regions. The rates are higher in immunosuppressed patients. There is a potential association between HHV-8 and type 2 diabetes.
View Article and Find Full Text PDFViral Immunol
September 2025
Chengdu Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences, Chengdu, China.
To assess the dynamics of humoral immune responses to inactivated SARS-CoV-2 vaccines across populations with and without prior COVID-19 infection, a longitudinal cohort study was conducted. A total of 38 COVID-19-recovered individuals and 165 naïve participants (without prior COVID-19 infection) were enrolled, all of whom completed a two-dose vaccination regimen. Levels of anti-spike (anti-S) and anti-nucleocapsid (anti-N) antibodies were analyzed at baseline and post-vaccination time points, including 6 weeks post-first dose, and 1 month and 6 months post-second dose.
View Article and Find Full Text PDF